HUP0200223A2 - Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them - Google Patents
Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing themInfo
- Publication number
- HUP0200223A2 HUP0200223A2 HU0200223A HUP0200223A HUP0200223A2 HU P0200223 A2 HUP0200223 A2 HU P0200223A2 HU 0200223 A HU0200223 A HU 0200223A HU P0200223 A HUP0200223 A HU P0200223A HU P0200223 A2 HUP0200223 A2 HU P0200223A2
- Authority
- HU
- Hungary
- Prior art keywords
- inhibitors
- tace
- mmp
- tnf
- preparation
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 2
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 title 1
- 102000043279 ADAM17 Human genes 0.000 title 1
- 108091007505 ADAM17 Proteins 0.000 title 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 title 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 125000000304 alkynyl group Chemical group 0.000 title 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23803899A | 1999-01-27 | 1999-01-27 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0200223A2 true HUP0200223A2 (en) | 2002-06-29 |
| HUP0200223A3 HUP0200223A3 (en) | 2002-12-28 |
Family
ID=22896246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0200223A HUP0200223A3 (en) | 1999-01-27 | 2000-01-27 | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them |
Country Status (13)
| Country | Link |
|---|---|
| JP (1) | JP2002535390A (en) |
| KR (1) | KR20010101732A (en) |
| AR (1) | AR035312A1 (en) |
| AT (1) | ATE309986T1 (en) |
| AU (1) | AU769418B2 (en) |
| CA (1) | CA2356313A1 (en) |
| CZ (1) | CZ20012711A3 (en) |
| DE (1) | DE60024056D1 (en) |
| EA (1) | EA200100806A1 (en) |
| HU (1) | HUP0200223A3 (en) |
| IL (1) | IL144345A0 (en) |
| NZ (1) | NZ512566A (en) |
| ZA (1) | ZA200105222B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4566006B2 (en) * | 2002-12-26 | 2010-10-20 | カルナバイオサイエンス株式会社 | Alkynyl-substituted azasugar derivatives and drugs containing the same as active ingredients |
| CA2656398A1 (en) * | 2006-06-30 | 2008-01-10 | Schering Corporation | Substituted piperidines that increase p53 activity and the uses thereof |
| WO2009147389A2 (en) * | 2008-06-02 | 2009-12-10 | Cipla Limited | Processes for the synthesis of levocetirizine and intermediates for use therein |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE263554T1 (en) * | 1997-02-27 | 2004-04-15 | Wyeth Corp | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYL AMIDES AS MATRIX METALLOPROTEINASE INHIBITORS |
| HUP0101837A3 (en) * | 1998-02-19 | 2001-11-28 | American Cyanamid Co Madison | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted-alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors |
-
2000
- 2000-01-26 AR ARP000100327A patent/AR035312A1/en not_active Application Discontinuation
- 2000-01-27 CA CA002356313A patent/CA2356313A1/en not_active Abandoned
- 2000-01-27 EA EA200100806A patent/EA200100806A1/en unknown
- 2000-01-27 CZ CZ20012711A patent/CZ20012711A3/en unknown
- 2000-01-27 NZ NZ512566A patent/NZ512566A/en unknown
- 2000-01-27 JP JP2000595979A patent/JP2002535390A/en active Pending
- 2000-01-27 AU AU26305/00A patent/AU769418B2/en not_active Ceased
- 2000-01-27 AT AT00904569T patent/ATE309986T1/en not_active IP Right Cessation
- 2000-01-27 HU HU0200223A patent/HUP0200223A3/en unknown
- 2000-01-27 KR KR1020017009432A patent/KR20010101732A/en not_active Application Discontinuation
- 2000-01-27 IL IL14434500A patent/IL144345A0/en unknown
- 2000-01-27 DE DE60024056T patent/DE60024056D1/en not_active Expired - Lifetime
-
2001
- 2001-06-25 ZA ZA200105222A patent/ZA200105222B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2356313A1 (en) | 2000-08-03 |
| AU2630500A (en) | 2000-08-18 |
| ATE309986T1 (en) | 2005-12-15 |
| KR20010101732A (en) | 2001-11-14 |
| EA200100806A1 (en) | 2002-08-29 |
| CZ20012711A3 (en) | 2002-05-15 |
| AR035312A1 (en) | 2004-05-12 |
| AU769418B2 (en) | 2004-01-29 |
| JP2002535390A (en) | 2002-10-22 |
| ZA200105222B (en) | 2002-09-25 |
| DE60024056D1 (en) | 2005-12-22 |
| NZ512566A (en) | 2004-02-27 |
| HUP0200223A3 (en) | 2002-12-28 |
| IL144345A0 (en) | 2002-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000641A3 (en) | Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them | |
| HUP0402263A3 (en) | Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| AU2002357312A1 (en) | Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases | |
| HUP0201680A3 (en) | Aromatic sulfone hydroxamic acid derivatives metalloprotease inhibitors and pharmaceutical compositions containing them | |
| AU2003282920A8 (en) | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| IL136300A0 (en) | Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors | |
| HUP0103344A3 (en) | Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp), process for their preparation and pharmaceutical compositions containing them | |
| HUP0201214A2 (en) | Inhibitors of impdh enzyme, pharmaceutical compositions containing them and their use | |
| HUP0300195A3 (en) | Heterocyclic sodium/proton exchange inhibitors and pharmaceutical compositions containing them | |
| HUP0200347A2 (en) | N-cyanomethylamides as protease inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0103452A3 (en) | Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds | |
| AU2002341715A1 (en) | Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace) | |
| AU2003220401A8 (en) | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases | |
| HK1045501A1 (en) | Hydroxamic acid derivatives as matrix metalloprotease inhibitors | |
| HUP0200213A2 (en) | Alkynyl containing hydroxamic acid compounds as tace inhibitors, process for their preparation and pharmaceutical compositions containing them | |
| AU6764400A (en) | Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors | |
| NO20013678L (en) | Alkynyl-Containing Hydroxamic Acid Derivatives, Their Preparation, and Their Use of Summer Matrix Metalloproteinase (MMP) Inhibitors / TNF <alpha> | |
| HUP0101899A3 (en) | Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes, pharmaceutical compositions comprising thereof and their use | |
| HUP0200223A2 (en) | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors and pharmaceutical compositions containing them | |
| AU2201701A (en) | Hydroxamic acid derivatives as matrix metalloproteinase (mmp) inhibitors | |
| HUP0003880A3 (en) | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors, pharmaceutical compositions thereof and process for the preparation of the same | |
| HUP0203118A3 (en) | Beta disubstituted metalloprotease inhibitors, pharmaceutical compositions containing them and their use | |
| HUP0200729A3 (en) | Hydroxamic acid derivatives, their use and preparation and pharmaceutical compositions containing them | |
| HUP0203270A3 (en) | Hydroxamic acid derivative as inhibitor of the formation of human cd23, process for its preparation and pharmaceutical compositions containing the same | |
| HUP0200605A3 (en) | Hydroxamic acid derivatives, their preparation and use and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |